There's been an alarming increase of respiratory and gastrointestinal viruses in the United States lately, causing anxiety about a so-called "quad-demic". According to surveillance reports, influenza, COVID-19, RSV and norovirus are at very high levels everywhere. While the surge aligns with patterns typical for this season, several epidemiologists view simultaneous infections of such proportions to pose risks not only to individual healthcare but public health.

The incidence of the quad-demic should vary with seasonal patterns, vaccination rates, and public health interventions. Each virus alone is relatively easy to manage; however, the effect of all together could lead to overburdening of health care facilities and increase risks for those at higher risk. Continuing surveillance, early testing, and proactive prevention measures will play an important role in the control of these infections going forward.

While the term "quad-demic" sounds daunting, it must be taken into perspective. For years, we have had all these viruses together, and we have the capabilities to mitigate some of the risk. Vaccination, proper hygiene and using common sense helps individuals get through the season unscathed. Is the quad-demic a permanent fixture or just another seasonal wave? Let's break this down.

What is the Quad-demic?

Typically, flu, COVID-19, and RSV have been the primary culprits behind seasonal respiratory infections. However, norovirus, a highly contagious stomach bug, has emerged as a fourth significant player, inducing fears of a more severe and widespread viral outbreak. According to the Centers for Disease Control and Prevention (CDC), the U.S. recorded nearly 500 norovirus outbreaks between August and December 2023, a substantial rise from the previous year’s numbers.

While the term "quad-demic" may sound ominous, the seriousness and consequences of such infections should be weighed in light of the U.S. healthcare system's experience with managing viral surges since the start of the COVID-19 pandemic.

1. Influenza (Flu)

Flu continues to be one of the most common and alarming seasonal illnesses. In the period spanning from 2023 to 2024, there were approximately 40 million cases of flu, and thousands of hospitalizations along with reported 47 deaths have been reported this season. Flu symptoms include fever, chills, cough, sore throat, muscle pain, and fatigue, with most recovering within a week or two but risky factors for severe illness effects occur in young children, elderly, and people with chronic conditions.

2. Covid-19

Despite its reduction from the first pandemic peak, COVID-19 is still rampant. The CDC estimates that alone between October and December 2023, there were between 2.7 and 5 million cases in the U.S. Hospitalization has increased by cities such as Los Angeles, Chicago, and New York. Symptoms are closely similar to the flu, fever, cough, and fatigue but uniquely presents in some cases as loss of taste and smell.

3. RSV

RSV is the most common cause of lower respiratory infections in infants, older adults, and immunocompromised individuals. While RSV peaked late in 2023 and early 2024, it continues to be a threat because it can lead to bronchiolitis and pneumonia. It is very similar to the common cold, presenting with symptoms such as congestion, runny nose, coughing, and fever, which can make it difficult to differentiate from flu or COVID-19 without testing.

4. Norovirus

Norovirus, also called the "stomach flu," is a highly contagious infection of the gastrointestinal tract, not a respiratory virus. It transmits quickly from contaminated food and water and contact with contaminated surfaces, causing such symptoms as diarrhea, vomiting, nausea, and stomach pain. Cases have shot up, the CDC said Monday, with reports of outbreaks surging compared with last year.

Is There a Challenge In Diagnosis Due to Overlapping Symptoms?

The greatest challenge during the quad-demic is how the four viruses are alike and thus make identification very hard with no testing applied. Most cases present symptoms common to all viruses: fever, tiredness, body pains, and respiratory, which includes coughing and congestions for influenza, COVID-19, and RSV; the other would be norovirus symptoms as nausea and vomiting can appear even in extreme influenza and COVID-19. This overlap increases the risk of misdiagnosis and delayed treatment, hence the need for early testing and proper medical guidance.

Also Read: Is US Preparing For A Quad- demic 2025?

Effective Prevention Strategies That Work

The best defense against these viruses is a combination of vaccines, hygiene, and lifestyle precautions. While lifestyle modifications are highlighted as part of the constant need to eat healthy, ensure daily movement and drinking adequate amount of fluids. There is a sure short two preventive strategies that are effective:

Vaccination

• Flu vaccine: Annual flu shots reduce the severity of infection, allergic flare ups and hospitalizations.
• COVID-19 vaccine: Though COVID-19 cases have declined, vaccination remains critical in preventing severe outcomes.
• RSV vaccine: Available for those aged 60 years and older, especially those with underlying conditions.
• Norovirus vaccine: No vaccine is yet available, but mRNA vaccine research is in progress.

Hygiene and Sanitation

• Washing hands frequently with soap and water for at least 20 seconds, especially after public exposure.
• Disinfect frequently touched surfaces regularly, use sanitiser when outside.
• Avoid close contact with infected people and wear masks.

Do You Need To Wear A Mask All The Time?

While debates on masked wear continue on, experts on mask-wear affirm that this does not only have a historical precedent but works towards reducing airborne viruses spreading within the environments. Hospitals, though, ensure masking in key sections of themselves. Publicized mask-wear remains a discretion, though massing indoors still goes a longer way in cases like peak flu seasons.

If you notice the symptoms of these viruses, then it's best to be confined at home and avoid having face-to-face interaction with others and seek immediate attention from your physician if your condition worsens. Quarantining for some days can decrease the spread of infection.

As we move into the first half of 2025 and beyond, staying informed and proactive is the best strategy for maintaining health and avoiding unnecessary panic. The key takeaway? Stay vigilant, but don’t be alarmed—these viruses are here, but so are the means to fight them.

The makers of blockbuster weight-loss drugs Novo Nordisk and Eli Lilly are locked in a legal battle after Novo accused its rival of misleading advertising by claiming its obesity and diabetes medicines outperform Novo's treatments.

Danish drugmaker Novo Nordisk has filed a lawsuit against Eli Lilly in the US District Court in New Jersey, alleging the company violated federal and state false advertising and unfair competition laws, including the Lanham Act, through nationwide advertising campaigns for its obesity drug Zepbound and diabetes treatment Mounjaro, media reports said.

Novo Alleges Ads Used Outdated Comparisons

Novo claims Lilly's advertisements:

• Compared the highest approved doses of Zepbound and Mounjaro with lower doses of Novo's Wegovy and Ozempic.
• Omitted data on the newer 7.2 mg dose of Wegovy, which, as per Novo, delivers greater weight loss.
• Relied on older clinical trial data that no longer reflects current approved dosing.

"The ads are maliciously and deceptively false because Lilly knowingly cites outdated clinical trials that compare the highest doses of the Lilly medicines to lower doses of Novo Nordisk's medicines," Novo said in its complaint.

Also read: Novo Nordisk's GLP-1 Drug Wegovy Approved for Fatty Liver Disease in India

What Did Eli Lilly Say

Eli Lilly rejected the allegations, saying its advertisements accurately reflect findings from its SURMOUNT-5 clinical trial.

According to the company:

• The study, completed in 2024, compared 10 mg and 15 mg doses of Zepbound with 1.7 mg and 2.4 mg doses of Wegovy.
• Novo's 7.2 mg Wegovy received US FDA approval only in March 2026, after the trial had concluded.

"Rather than compete on the merits of its products, Novo is asking a court to stop Lilly from communicating the results of that trial," an Eli Lilly spokesperson said. "We will continue to focus on the science and defend against this lawsuit vigorously."

Battle For Expanding Obesity Market

The lawsuit comes as Novo Nordisk and Eli Lilly compete for dominance in the rapidly expanding US obesity drug market, which analysts expect to exceed $100 billion by 2030.

Both companies dominate the GLP-1 medicine market:

• Novo Nordisk's medicines contain semaglutide.
• Eli Lilly's medicines contain tirzepatide.

These medicines:

• Mimic the GLP-1 hormone.
• Slow digestion.
• Help regulate blood sugar.
• Suppress appetite.

Beyond weight loss, studies have shown that GLP-1 medicines can reduce the risk of major cardiovascular events, including heart attack and stroke, and may also lower the risk of several cancers.

WHO Guidance on GLP-1 Therapies

In December 2025, the World Health Organization (WHO) issued its first guideline on the use of GLP-1 therapies for obesity, describing the condition as a chronic, relapsing disease affecting more than 1 billion people worldwide. It recommends:

• GLP-1 therapies may be used for long-term obesity treatment in adults, excluding pregnant women.
• Treatment should be combined with structured lifestyle interventions, including a healthy diet, regular physical activity, and behavioral support to improve outcomes.

Will Patients Be Affected?

For now, patients are unlikely to be affected. The lawsuit does not challenge the safety, effectiveness, or FDA approval of the medicines. Instead, it focuses solely on how Eli Lilly marketed its products.

Patients prescribed the medicines Wegovy and Ozempic (Novo Nordisk) or Zepbound and Mounjaro (Eli Lilly) can continue taking them as directed.

Any outcome of the case is more likely to influence how pharmaceutical companies advertise and compare their medicines than the availability of these treatments.

France has passed landmark legislation banning children under the age of 15 from accessing social media, becoming the first country in the European Union to adopt the policy.

The move comes amid growing global concern over the impact of social media on young people's mental health, online safety, and overall well-being.

The law, approved by both houses of the French Parliament on July 21, is expected to come into force on September 1, 2026, before the start of the new school year.

The move arrives after months of debate over increasing rates of cyberbullying, excessive screen time, exposure to harmful online content, and the effects of social media on children's mental health.

France Bans Social Media For Children Under 15

Children younger than 15 will no longer be allowed to create or maintain accounts on social media platforms.

Tech companies operating these platforms will be required to implement watertight age-verification systems as well as remove existing accounts belonging to underage users.

French President Emmanuel Macron who has repeatedly voiced concerns about the effects of excessive screen time and social media on children and adolescents, described the legislation as "a major step towards protecting our children" and said the aim is to help young people grow into "responsible citizens" in an increasingly digital world.

The legislation is aimed at reducing risks associated with:

• Anxiety and depression
• Cyberbullying
• Self-harm and suicide-related content
• Sleep disruption
• Exposure to inappropriate or harmful material
• Social media addiction

Also read: Rain = No Playground; How Reduced Outdoor Activity During Monsoon Affects Children's Immunity, Weight & Mental Health

Although the law has received political support, experts say implementation may prove challenging. Technology companies have long argued that verifying users' ages at a large scale is technically complex and raises concerns over data protection.

The legislation may also face legal scrutiny regarding compatibility with European Union digital regulations and constitutional protections before full implementation.

France is not the first nation to tighten restrictions on children's social media use. Australia became the first country to introduce a nationwide ban for children under 16 on platforms like Facebook, Snapchat, TikTok and YouTube.

Several European nations, including Greece, Germany, Denmark and Spain, are considering similar measures.

Can A Social Media Ban Positively Impact Children's Mental Health?

HealthandMe spoke to Dr. Nivedha P, MD Psychiatry, Athulya Geriatric Care Hospital, about the impact social media has on young, developing brains and if a ban can truly improve their mental health.

She says, "As a psychiatrist, I understand why countries are becoming concerned. Today, children are growing up in a digital world, and social media has become a part of their everyday life. But at the same time, we’re seeing more anxiety, low self-esteem, sleep problems, cyberbullying, and even symptoms of depression among young people. So, the concern is definitely real.

Talking about if a social media ban for pre-pubescents and teenagers could help, she says that a ban alone is not enough to regulate screen time among children.

Also read: Babies Without Vitamin K Shot At Higher Risk Of Brain Bleeding: Study

She explains, "It may help to some extent because it reduces early exposure during a very sensitive stage of brain development. But I don’t think a ban alone is the answer."

The expert says that technology isn’t going anywhere. The goal shouldn’t be to make children afraid of technology, but to help them become emotionally mature enough to use it wisely. The best approach, according to her, is a combination of sensible regulations, parental guidance, digital literacy, and creating safe online spaces.

She adds, "If a child doesn’t learn how to use technology in a healthy way, they’ll eventually face the same challenges when they gain access later. So, instead of only saying ‘don’t use social media,’ we should also teach children how to use it responsibly."

The Quality Of Offline Life Matters

According to the expert, parents also have a huge role in ensuring children do not get addicted to social media. Many children don’t need more screen time, they need more conversations, more play, more family time, and adults who model healthy digital habits.

Dr. Nivedha says, "We often focus on what children are doing online, but we should also ask what kind of offline life we’re creating for them."

At the end of the day, protecting children’s mental health is not just the responsibility of governments. It’s a shared responsibility between parents, schools, healthcare professionals, technology companies and society as a whole.

She adds, "A ban may buy us some time, but what truly protects a child’s mental health is teaching them emotional resilience, healthy relationships and responsible digital habits."

Paul Alexander woke up inside a 600-pound giant metal tube and never left until he died. Paul depended on an iron lung for every breath, a machine that had largely disappeared from modern medicine.

Known as "the man in the iron lung," Alexander spent more than seven decades living inside the metal cylinder after contracting polio as a child. Paul became a symbol of resilience, determination, and the life-saving power of vaccines. His remarkable story is recalled even after his death in March 2024 at the age of 78.

Who Was Paul Alexander?

The doctors placed him inside an iron lung, a mechanical ventilator that kept him alive by helping his lungs expand and contract.

Although everyone initially believed he might not survive, Alexander defied expectations. He went on to graduate from college, earn a law degree, become a practicing attorney, publish a memoir, and inspire millions through interviews and social media.

Also read: Who Was Martha Lillard? Last U.S. Polio Survivor To Depend On An Iron Lung Who Breathed Her Last At 78

Life Beyond The Iron Lung

Paul Alexander refused to let the machine define him. Doctors taught him a technique called "frog breathing" or glossopharyngeal breathing. By using the muscles of his mouth and throat, he learned to gulp air into his lungs in small amounts.

This helped him to leave the iron lung for short durations, attend school, pursue higher education, and eventually work as a lawyer. Still, he depended on the iron lung for most of his life, especially while sleeping.

Despite his conditions, Alexander earned a bachelor's degree, graduated from law school, practiced as a lawyer in Texas, and wrote his memoir - Three Minutes for a Dog: My Life in an Iron Lung.

His determination challenged and defied assumptions about disability and demonstrated that severe physical limitations need not prevent education, work, or meaningful relationships.

Also read: Even Light Exercise Could Help People With COPD Live Longer, Study Finds

Iron Lung Is An Obsolete Technology In Medicine

An iron lung, also called a negative-pressure ventilator, is a large cylindrical machine that helps people breathe when the muscles controlling respiration become paralyzed.

Unlike today's ventilators, which push air directly into the lungs through a tube or mask using positive pressure, an iron lung works by changing air pressure around the patient's body. The patient lies inside an airtight metal chamber with only the head remaining outside.

The machine then repeatedly lowers the air pressure inside the chamber. This causes the chest to expand naturally, drawing air into the lungs. The pressure then returns to normal. The chest relaxes, allowing air to flow back out. This cycle mimics normal breathing and can continue around the clock.

Iron lungs became obsolete eventually after polio vaccines and modern ventilators were developed.

The introduction of effective polio vaccines in the 1950s and 1960s dramatically reduced cases of paralytic polio worldwide.

The positive-pressure ventilators we use today are smaller, more portable, and better suited to intensive care. They deliver oxygen directly into the lungs, replacing bulky iron lungs.

Paul Alexander's life is more than a remarkable survival story. It serves as a reminder of the devastating impact infectious diseases once had before vaccines transformed public health.